Hyperuricemia treatment: is creatinine clearance a safer allopurinol dosing meter than plasma creatinine levels?
Robert Terkeltaub
Correspondence VAMC Rheumatology Section, University of California San Diego, Rheumatology Allergy-Immunology Division, Veterans Affairs Medical Center, 3350 La Jolla Village Drive, San Diego, CA 92161, USA
Email rterkeltaub@ucsd.edu
This article has no abstract so we have provided the first paragraph of the full text.
The prevalence of gout has approximately doubled in the last two decades in the US and has been associated with several factors including increased longevity, hypertension, obesity, metabolic syndrome, type II diabetes mellitus, and advanced renal insufficiency.1, 2 This increase in gout prevalence has been particularly marked in those over 65 years of age.2 Ageing and renal insufficiency alter the pharmacokinetics of several drugs used to treat hyperuricemia or gouty arthritis, including colchicine, nonsteroidal anti-inflammatory drugs, and allopurinol.3 The management of gout has, therefore, become more clinically complex.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
